Zegerid OTC arrives in April
This article was originally published in The Tan Sheet
Executive Summary
Zegerid OTC is slated to ship in late March and reach retail by April, says Santarus, the originator of the switched proton pump inhibitor. The firm reported March 3 its fourth-quarter earnings climbed 66.3 percent to $62.4 million - driven mainly by a $20 million regulatory approval milestone payment from Merck, which will market Zegerid OTC (omeprazole/sodium bicarbonate). Santarus said it expects to know by June whether FDA will allow an already-approved dual-buffer PPI to be marketed under the Zegerid brand
You may also be interested in...
Zegerid Ad Focuses On Science As Competitors Seek Emotional Connection
The first television campaign for Zegerid OTC emphasizes the science behind the heartburn drug's unique dual-ingredient formula
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.